当前位置: 首页 > 期刊 > 《中外医疗》 > 2017年第33期
编号:13212697
TOPOⅡα联合Ki67预测三阴性乳腺癌新辅助化疗疗效的临床应用价值(3)
http://www.100md.com 2017年11月25日 中外医疗 2017年第33期
     [4] 桑蝶,王佳玉.Ki67與乳腺癌临床病理特征及新辅助化疗疗效的相关性[J].癌症进展,2015,13(3):291-297.

    [5] Hertel PB,Tu D,lertseu B,et a1.T1MP-I in combination with HER2 and TOPOⅡα for prediction of benefit from adjuvant anthracyclines in high risk breast cancer patients [J].Breast Cancer Res Treat,2012,132(1):225-234.

    [6] Mitrovic O,Cokic V,Dikic D,et al.Correlation between ER、PR 、HER2、Bcl-2、p53 proliferative and apoptotic indexes with HER2 gene amplification and TOPOⅡαgene amplification and deletion in four molecular subtypes of breast cancer[J].Target Oncol,2014,9(4):367-379.

    [7] Moretti E,Desmedt C,Biagioni C,et a1.TOPOⅡαprotein by quantitative immunofluoreseenee as a predictor of response to epirubiein in the neoadjuvant treatment of breast cancer[J].FutureOncol,2013,9(10):1477-1487.

    [8] Klintman M,Buus R,Cheang MC,et a1.Changes in Expression of Genes Representing Key Biologic Processes after Neoadjuvant Chemotherapy in Breast Cancer,and Prognostic Implications in Residual Disease[J].Clin Cancer Res,2016,22(10):2405-2416.

    (收稿日期:2017-08-25), 百拇医药(韩忠华 林舜国 许春森 韩晖)
上一页1 2 3